Applied BioMath Assess™ can be used to optimize the design of CD3 bispecific T-cell engagers by evaluating the risk of on-target, off-tumor toxicities and to make an early prediction about therapeutic index and projections of effective and tolerable doses for T-cell engagers in solid tumors. In this case study, we will demonstrate the ability to predict the on-target, off-tumor toxicity observed for solitomab, a drug that failed to meet its end points due to dose limiting toxicity. We will use this model to identify properties of tumor-associated antigens that could be more successfully targeted with a TCE. Furthermore, we will explore the feasibility of next generation T-cell engager molecules to enhance tissue selectivity leading to improved therapeutic index (TI).
View the video demo